Pharma: Page 17
-
Permission granted by Ron Tilles, Kevin Mercuri
ProfileLeft to clean up after ‘pharma bro’ Shkreli’s arrest, former Turing CEO Ron Tilles reckons with the past
While Martin Shkreli smirked his way through a public securities fraud investigation, Ron Tilles became interim CEO of Turing Pharmaceuticals, ready or not. Here’s his story.
By Michael Gibney • Nov. 14, 2024 -
Getty Images
From Mr. Mucus to the Super Bowl, pharma tries offbeat marketing strategies
As the industry’s marketing dollars shift, companies are targeting potential patients in unique ways.
By Amy Baxter • Nov. 13, 2024 -
Explore the Trendline➔
Getty Images
TrendlineArtificial intelligence & machine learning
After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.
By PharmaVoice staff -
Getty Images
Pharma’s grip on cancer R&D is having unintended consequences
A pair of studies paint a complicated picture of funding and missed research opportunities.
By Alexandra Pecci • Nov. 12, 2024 -
Permission granted by Pfizer
Pfizer and Lilly’s telehealth prescribing platforms draw Senate scrutiny for ‘potential fraud’
As Big Pharma embraces telehealth to sell medicines directly to patients, lawmakers wonder whether the programs skirt anti-kickback rules.
By Kelly Bilodeau • Nov. 12, 2024 -
Getty Images
Spravato is just the beginning in a new wave of depression meds
Psychiatry is getting more targeted as drugmakers develop a new range of treatments for depression.
By Meagan Parrish • Nov. 11, 2024 -
Michael M. Santiago via Getty Images
What RFK Jr.’s influence could mean for pharma
Past comments hint at the changes Robert F. Kennedy Jr. could make across the various sectors of healthcare.
By Amy Baxter • Nov. 8, 2024 -
Chip Somodevilla via Getty Images
With Trump victorious, biotech industry’s focus turns to his plans for FDA, FTC
Speculation around pharma dealmaking and the next FDA commissioner has begun.
By Ned Pagliarulo , Ben Fidler • Nov. 8, 2024 -
Getty Images
Among 2024’s modest M&A action, cancer, immunology and neuroscience deals trickle in
Dealmaking this year has been largely muted, but M&A trends are pointing to the areas where pharma is placing the most emphasis.
By Michael Gibney • Nov. 7, 2024 -
Jacob Bell/PharmaVoice
An RNAi renaissance is creating a new generation of startups
Pioneers like Alnylam Pharmaceuticals have led the RNA interference field for years. Now, a crop of young biotechs is building on that foundation by taking the drugmaking technology in new directions.
By Gwendolyn Wu • Nov. 7, 2024 -
Getty Images
A diabetes drug, twice rejected, stumbles again — but its developer persists
After multiple rejections, Lexicon Pharmaceuticals is inching toward an FDA decision date next month for its adjunct type 1 diabetes therapy.
By Amy Baxter • Nov. 6, 2024 -
Permission granted by Sernova
ProfileCEO with type 1 diabetes works to deliver ‘world’s first’ functional cure
Sernova’s technology helped type 1 diabetes patients achieve insulin independence in early- and mid-stage trials.
By Alexandra Pecci • Nov. 5, 2024 -
Getty Images
Pharma takes aim at a wily foe — the Epstein-Barr virus
The pernicious and widespread virus has been linked to a range of diseases including MS and long COVID.
By Kelly Bilodeau • Nov. 4, 2024 -
Spencer Platt / Staff via Getty Images
Pfizer’s quest for market share in the ‘high stakes battleground’ of oral GLP-1s
Pfizer’s second-to-market goals for its oral GLP-1 drugs underscore big opportunities in the space.
By Amy Baxter • Nov. 4, 2024 -
Getty Images
A sickle cell cure exists. But patients need more than just gene therapy.
Almost a year after two historic approvals, Pfizer is pulling a sickle cell disease treatment from the market, and the outlook for patients feels shakier.
By Alexandra Pecci • Nov. 1, 2024 -
Photo illustration: Industry Dive; Getty Images
PharmaVoice 1002024 PharmaVoice 100s: Cancer Care Visionaries
Leaders who envision a world without cancer through oncology innovation.
By Michael Gibney • Nov. 1, 2024 -
Getty Images
Big Pharma earnings hang hope on the next generation of blockbusters
Pfizer, J&J, Biogen and Novartis are banking on new products to make up for maturing blockbusters, but future growth is not guaranteed.
By Michael Gibney • Oct. 31, 2024 -
Photo illustration: Industry Dive; Getty Images
PharmaVoice 1002024 PharmaVoice 100s: Clinical Trial Pros
Experts raising the bar in clinical trial design and collaboration.
By Amy Baxter • Oct. 31, 2024 -
Getty Images
Backlash builds against Novo’s Catalent takeover
Roche recently joined naysayers who argue the deal threatens competition in the burgeoning weight loss and diabetes drug market.
By Amy Baxter • Oct. 30, 2024 -
Photo illustration: Industry Dive; Getty Images
PharmaVoice 1002024 PharmaVoice 100s: Rare Disease Warriors
Pharma pros driving drug development and access for patients with high unmet needs.
By Meagan Parrish • Oct. 29, 2024 -
Getty Images
Q&AHow AZ’s respiratory wins are ramping up for a bigger prize in COPD
As AstraZeneca builds up indications for Fasenra, an ongoing trial will determine whether the respiratory drug can make up for past stumbles in COPD.
By Michael Gibney • Oct. 29, 2024 -
Mario Tama via Getty Images
Where Big Pharma’s campaign cash is flowing in this election
Big Pharma CEOs are hedging all bets by supporting both sides of the aisle in the 2024 election.
By Amy Baxter • Oct. 28, 2024 -
Getty Images
On the front lines of the superbug war, new treatments can’t arrive soon enough
As antimicrobial resistance rises, researchers are running out of time to fight each new wave of superbugs. And the funding isn’t enough.
By Kelly Bilodeau • Oct. 28, 2024 -
Mario Tama via Getty Images
J&J’s comeback kid Spravato heads for blockbuster status
After a slow start, the novel esketamine nasal spray for depression is now J&J’s fastest-growing medication.
By Meagan Parrish • Oct. 25, 2024 -
Getty Images
Why pharma megamergers may become a relic of the past
Despite pent up M&A demand, FTC scrutiny has had a chilling effect on pharma’s appetite for striking major deals.
By Kelly Bilodeau • Oct. 24, 2024 -
Buda Mendes via Getty Images
Dengue is spreading and Sanofi is pulling the U.S. market’s only vaccine. What’s next?
As Sanofi prepares to halt production on its dengue vaccine in 2026, locally acquired infections in the U.S. are raising the alarm.
By Alexandra Pecci • Oct. 23, 2024
Previous
